跳到正文
原文
STAT 主站· Elaine Chen·· 23 天前精选AI 评分71

礼来候选药物retatrutide与诺和诺德Ozempic糖尿病疗效对比

STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study

AI 导读

礼来公司称其候选药物retatrutide在糖尿病治疗中优于诺和诺德Ozempic,数据显示高剂量组A1c降低2.2个百分点且减重20.9%,但结果仅基于持续治疗者分析。

推荐理由

原文对比了两种药物在糖尿病治疗中的疗效差异,为同类药物研发提供参考

正文

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Eli Lilly on Wednesday said that its investigational drug was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study, further boosting the competitive profile of its medicine.

In the head-to-head study, people on the highest dose of Lilly’s drug, called retatrutide, saw a 2.2 percentage-point reduction in a measure of blood sugar called A1c after 80 weeks, while those on Ozempic saw a 1.8 percentage-point reduction.

Those on the highest dose of retatrutide also lost 20.9% of their weight, a highly significant amount considering that people with diabetes don’t tend to lose much weight on drugs. Meanwhile, those taking Ozempic lost 9.4% of their weight. These results are based on analyses looking only at the participants who stayed on treatment, not all participants.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com